Keywords:
мелатонин; ожирение; липидный обмен; механизмы; инсулин; глюкоза; лептин.References
Tan, D.X.; Hardeland, R.; Back, K.; Manchester, L.C.; Alatorre-Jimenez, M.A.; Reiter, R.J. On the significance of an alternate pathway of melatonin synthesis via 5-methoxytryptamine: Comparisons across species. J. Pineal Res. 2016, 61, 27–40. [CrossRef] [PubMed]
Hardeland, R.; Madrid, J.A.; Tan, D.X.; Reiter, R.J. Melatonin, the circadian multioscillator system, and health: The need for detailed analyses of peripheral melatonin signaling. J. Pineal Res. 2012, 52, 139–166. [CrossRef]
Reppert, S.M.; Weaver, D.R. Melatonin madness. Cell 1995, 83, 1059–1062. [CrossRef] 6. Socaciu, A.I.; Ionu¸t, R.; Socaciu, M.A.; Ungur, A.P.; Bârsan, M.; Chiorean, A.; Socaciu, C.; Râjnoveanu, A.G. Melatonin, an ubiquitous metabolic regulator: Functions, mechanisms, and effects on circadian disruption and degenerative diseases. Rev. Endocr. Metab. Disord. 2020, 21, 465–478. [CrossRef]
Ma, N.; Zhang, J.; Reiter, R.J.; Ma, X. Melatonin mediates mucosal immune cells, microbial metabolism, and rhythm crosstalk: A therapeutic target to reduce intestinal inflammation. Med. Res. Rev. 2020, 40, 606–632. [CrossRef]
Bu, S.; Wang, Q.; Sun, J.; Li, X.; Gu, T.; Lai, D. Melatonin suppresses chronic restraint stress-mediated metastasis of epithelial ovarian cancer via NE/AKT/β-catenin/SLUG axis. Cell Death Dis. 2020, 11, 644. [CrossRef]
Scott E. M., Grant P. J. Neel revisited: the adipocyte, seasonality and type 2 diabetes //Diabetologia. – 2006. – Т. 49. – №. 7. – С. 1462-1466.
St-Onge M. P. et al. Sleep duration and quality: impact on lifestyle behaviors and cardiometabolic health: a scientific statement from the American Heart Association //Circulation. – 2016. – Т. 134. – №. 18. – С. e367-e386
Alonso‐Vale M. I. C. et al. Intermittent and rhythmic exposure to melatonin in primary cultured adipocytes enhances the insulin and dexamethasone effects on leptin expression //Journal of pineal research. – 2006. – Т. 41. – №. 1. – С. 28-34.
Romo-Nava, F.; Alvarez-Icaza González, D.; Fresán-Orellana, A.; Saracco Alvarez, R.; Becerra-Palars, C.; Moreno, J.; Ontiveros Uribe, M.P.; Berlanga, C.; Heinze, G.; Buijs, R.M. Melatonin attenuates antipsychotic metabolic effects: An eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial. Bipolar. Disord. 2014, 16, 410–421. [CrossRef]
Modabbernia, A.; Heidari, P.; Soleimani, R.; Sobhani, A.; Roshan, Z.A.; Taslimi, S.; Ashrafi, M.; Modabbernia, M.J. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: Randomized double-blind placebo-controlled study. J. Psychiatr. Res. 2014, 53, 133–140. [CrossRef]
Agil, A.; Navarro-Alarcón, M.; Ruiz, R.; Abuhamadah, S.; El-Mir, M.Y.; Vázquez, G.F. Beneficial effects of melatonin on obesity and lipid profile in young Zucker diabetic fatty rats. J. Pineal Res. 2011, 50, 207–212. [CrossRef] [PubMed] 34. Hussain, S.A. Effect of melatonin on cholesterol absorption in rats. J. Pineal Res. 2007, 42, 267–271. [CrossRef]
Pita, M.L.; Hoyos, M.; Martin-Lacave, I.; Osuna, C.; Fernández-Santos, J.M.; Guerrero, J.M. Long-term melatonin administration increases polyunsaturated fatty acid percentage in plasma lipids of hypercholesterolemic rats. J. Pineal Res. 2002, 32, 179–186. [CrossRef]
De Farias, T.; Cruz, M.; de Sa, R.; Severi, I.; Perugini, J.; Senzacqua, M.; Cerutti, S.; Giordano, A.; Cinti, S.; Alonso-Vale, M. Melatonin supplementation decreases hypertrophic obesity and inflammation induced by high-fat diet in mice. Front. Endocrinol. 2019, 10, 750. [CrossRef]
Ríos-Lugo, M.J.; Cano, P.; Jiménez-Ortega, V.; Fernández-Mateos, M.; Scacchi, P.; Cardinali, D.; Esquifino, A. Melatonin effect on plasma adiponectin, leptin, insulin, glucose, triglycerides and cholesterol in normal and high fat-fed rats. J. Pineal Res. 2010, 49, 342–348. [CrossRef]
Ou, T.H.; Tung, Y.T.; Yang, T.H.; Chien, Y.W. Melatonin improves fatty liver syndrome by inhibiting the lipogenesis pathway in hamsters with high-fat diet-induced hyperlipidemia. Nutrients 2019, 11, 748. [CrossRef]
Mohammadi-Sartang, M.; Ghorbani, M.; Mazloom, Z. Effects of melatonin supplementation on blood lipid concentrations: A systematic review and meta-analysis of randomized controlled trials. Clin. Nutr. 2018, 37, 1943–1954. [CrossRef]
Loloei, S.; Sepidarkish, M.; Heydarian, A.; Tahvilian, N.; Khazdouz, M.; Heshmati, J.; Pouraram, H. The effect of melatonin supplementation on lipid profile and anthropometric indices: A systematic review and meta-analysis of clinical trials. Diabetes Metab. Syndr. 2019, 13, 1901–1910. [CrossRef]
Koziróg, M.; Poliwczak, A.R.; Duchnowicz, P.; Koter-Michalak, M.; Sikora, J.; Broncel, M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J. Pineal Res. 2011, 50, 261–266. [CrossRef]
Parandavar, N.; Hojat, M.; Abdali, K.; Keshtgar, S.; Emamghoreishi, M.; Yeganeh, B.S. The effect of melatonin on the lipid levels in menopausal women: A double-blind, controlled, clinical trial. J. Educ. Health Promot. 2018, 7, 144. [CrossRef]
Chan, T.Y.; Tang, P.L. Effect of melatonin on the maintenance of cholesterol homeostasis in the rat. Endocr. Res. 1995, 21, 681–696. [CrossRef]
Tung, Y.T.; Chiang, P.C.; Chen, Y.L.; Chien, Y.W. Effects of melatonin on lipid metabolism and circulating irisin in Sprague-Dawley rats with diet-induced obesity. Molecules 2020, 25, 3329. [CrossRef]
She, M.H.; Deng, X.J.; Guo, Z.Y.; Laudon, M.; Hu, Z.W.; Liao, D.F.; Hu, X.B.; Luo, Y.; Shen, Q.Y.; Su, Z.H.; et al. NEU-P11, a novel melatonin agonist, inhibits weight gain and improves insulin sensitivity in high-fat/high-sucrose-fed rats. Pharmacol. Res. 2009, 59, 248–253. [CrossRef]
Kanter, M.; Uysal, H.; Karaca, T.; Sagmanligil, H.O. Depression of glucose levels and partial restoration of pancreatic beta-cell damage by melatonin in streptozotocin-induced diabetic rats. Arch. Toxicol. 2006, 80, 362–369. [CrossRef]
Li, T.; Ni, L.; Zhao, Z.; Liu, X.; Lai, Z.; Di, X.; Xie, Z.; Song, X.; Wang, X.; Zhang, R.; et al. Melatonin attenuates smoking-in duced. hyperglycemia via preserving insulin secretion and hepatic glycogen synthesis in rats. J. Pineal Res. 2018, 64, e12475. [CrossRef]
Lyssenko, V.; Nagorny, C.; Erdos, M.; Wierup, N.; Jonsson, A.; Spégel, P.; Bugliani, M.; Saxena, R.; Fex, M.; Pulizzi, N.; et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat. Genet. 2009, 41, 82–88. [CrossRef
Shieh, J.; Wu, H.; Cheng, K.; Cheng, J. Melatonin ameliorates high fat diet-induced diabetes and stimulates glycogen synthesis via a PKCzeta-Akt-GSK3beta pathway in hepatic cells. J. Pineal Res. 2009, 47, 339–344. [CrossRef]
Song, J.Y.; Zhang, H.J.; Wang, Z.Y.; Xu, W.L.; Zhong, L.; Cao, J.M.; Yang, J.F.; Tian, Y.; Yu, D.J.; Ji, J.; et al. The role of FABP5 in radiation-induced human skin fibrosis. Radiat. Res. 2018, 189, 177–186. [CrossRef]
Gomes, P.R.L.; Vilas-Boas, E.A.; Leite, E.A.; Munhoz, A.C.; Lucena, C.F.; Amaral, F.G.D.; Carpinelli, A.R.; Cipolla-Neto, J. Melatonin regulates maternal pancreatic remodeling and B-cell function during pregnancy and lactation. J. Pineal Res. 2021, 71, e12717. [CrossRef]
Picinato, M.; Hirata, A.; Cipolla-Neto, J.; Curi, R.; Carvalho, C.; Anhê, G.; Carpinelli, A. Activation of insulin and IGF-1 signaling pathways by melatonin through MT1 receptor in isolated rat pancreatic islets. J. Pineal Res. 2008, 44, 88–94. [CrossRef]
Chen, J.; Xia, H.Z.; Zhang, L.; Zhang, H.; Wang, D.; Tao, X. Protective effects of melatonin on sepsis-induced liver injury and dysregulation of gluconeogenesis in rats through activating SIRT1/STAT3 pathway. Biomed. Pharmacother. 2019, 117, 109150. [CrossRef]
Ha, E.; Yim, S.V.; Chung, J.H.; Yoon, K.S.; Kang, I.; Cho, Y.H.; Baik, H. Melatonin stimulates glucose transport via insulin receptor substrate-1/phosphatidylinositol 3-kinase pathway in C2C12 murine skeletal muscle cells. J. Pineal Res. 2006, 41, 67–72. [CrossRef]
Teodoro, B.; Baraldi, F.; Sampaio, I.; Bomfim, L.; Queiroz, A.; Passos, M.; Carneiro, E.; Alberici, L.; Gomis, R.; Amaral, F.; et al. Melatonin prevents mitochondrial dysfunction and insulin resistance in rat skeletal muscle. J. Pineal Res. 2014, 57, 155–167. [CrossRef]
Bazwinsky-Wutschke, I.; Wolgast, S.; Mühlbauer, E.; Albrecht, E.; Peschke, E. Phosphorylation of cyclic AMP-response elementbinding protein (CREB) is influenced by melatonin treatment in pancreatic rat insulinoma β-cells (INS-1). J. Pineal Res. 2012, 53, 344–357. [CrossRef]
Peschke, E.; Bähr, I.; Mühlbauer, E. Melatonin and pancreatic islets: Interrelationships between melatonin, insulin and glucagon. Int. J. Mol. Sci. 2013, 14, 6981–7015. [CrossRef]
Peschke, E.; Bähr, I.; Mühlbauer, E. Experimental and clinical aspects of melatonin and clock genes in diabetes. J. Pineal Res. 2015, 59, 1–23. [CrossRef] [PubMed]
Li, Y.L.; Wu, H.H.; Liu, N.J.; Cao, X.Y.; Yang, Z.; Lu, B.; Hu, R.M.; Wang, X.C.; Wen, J. Melatonin exerts an inhibitory effect on insulin gene transcription via MTNR1B and the downstream Raf-1/ERK signaling pathway. Int. J. Mol. Med. 2018, 41, 955–961. [CrossRef] [PubMed]
De Oliveira, A.; Andreotti, S.; Farias, T.S.; Torres-Leal, F.; de Proença, A.; Campaña, A.; de Souza, A.; Sertié, R.; Carpinelli, A.; Cipolla-Neto, J.; et al. Metabolic disorders and adipose tissue insulin responsiveness in neonatally STZ-induced diabetic rats are improved by long-term melatonin treatment. Endocrinology 2012, 153, 2178–2188. [CrossRef] [PubMed]
Cuesta, S.; Kireev, R.; García, C.; Rancan, L.; Vara, E.; Tresguerres, J. Melatonin can improve insulin resistance and aging-induced pancreas alterations in senescence-accelerated prone male mice (SAMP8). Age 2013, 35, 659–671. [CrossRef]
Sun, H.; Wang, X.; Chen, J.; Gusdon, A.; Song, K.; Li, L.; Qu, S. Melatonin treatment improves insulin resistance and pigmentation in obese patients with acanthosis nigricans. Int. J. Endocrinol. 2018, 2018, 2304746. [CrossRef] 63. Sartori, C.; Dessen, P.; Mathieu, C.; Monney, A.; Bloch, J.; Nicod, P.; Scherrer, U.; Duplain, H. Melatonin improves glucose homeostasis and endothelial vascular function in high-fat diet-fed insulin-resistant mice. Endocrinology 2009, 150, 5311–5317. [CrossRef]
McMullan, C.; Curhan, G.; Schernhammer, E.; Forman, J. Association of nocturnal melatonin secretion with insulin resistance in nondiabetic young women. Am. J. Epidemiol. 2013, 178, 231–238. [CrossRef]
De Luis, D.A.; Izaola, O.; Primo, D.; Aller, R. A circadian rhythm-related MTNR1B genetic variant (rs10830963) modulate body weight change and insulin resistance after 9 months of a high protein/low carbohydrate vs a standard hypocaloric diet. J. Diabetes Complicat. 2020, 34, 107534. [CrossRef]
Kwak, S.H.; Kim, S.H.; Cho, Y.M.; Go, M.J.; Cho, Y.S.; Choi, S.H.; Moon, M.K.; Jung, H.S.; Shin, H.D.; Kang, H.M.; et al. A genome-wide association study of gestational diabetes mellitus in Korean women. Diabetes 2012, 61, 531–541. [CrossRef]